[Ruxolitinib combined with venetoclax and azacitidine in the treatment of refractory T-ALL patients with JAK1, JAK3, and STAT5B gene mutations: a case report and literature review].Peipei Xu, B Chen, Y Y Xu et al.|PubMed|2024Cited by 1